Liraglutide Market: Size, Share, Growth, Analysis, Key Players, Revenue, Growth | Valuates Reports

Liraglutide Market
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-29O4198/Global_Liraglutide_Market_Research_Report_2021

Due to the COVID-19 pandemic, the global Liraglutide market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period 2023-2029.
Fully considering the economic change by this health crisis, Pills accounting for % of the Liraglutide global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029.
While Hospital segment is altered to an % CAGR throughout this forecast period.
The United States Liraglutide market is estimated at US$ million in 2022, while China was US$ million. The proportion of the United States is % in 2022, while Chinese percentage was %, and it is predicted that China share will reach % in 2029, trailing a CAGR of % through the analysis period.
The global key manufacturers of Liraglutide include HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide and AmbioPharm, etc. In 2022, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2022, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Get regional report
https://reports.valuates.com/request/regional/QYRE-Auto-29O4198/Global_Liraglutide_Market_Research_Report_2021

Liraglutide Market Size & Scope
The global Liraglutide market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Liraglutide market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
• Pills
• Liquid
Segment by Application
• Hospital
• Drug Store
BY COMPANY
• HEC Pharm
• Bachem
• Bharat Pharmaceuticals
• Kingpep Biotechnology
• Shenzhen JYMed Technology
• Wuxi Asiapeptide
• AmbioPharm
View full report
https://reports.valuates.com/market-reports/QYRE-Auto-29O4198/global-liraglutide

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.